Stereoselective metabolism of endosulfan by human liver microsomes and human cytochrome P450 isoforms

Drug Metabolism and Disposition

Volumn 34, Issue 7, 2006, Pages 1090-1095

  Lee, Hwa Kyung ^a   Moon, Joon Kwan ^a   Chang, Chul Hee ^a   Choi, Hoon ^a   Park, Hee Won ^a   Park, Byeoung Soo ^a   Lee, Hye Suk ^b   Hwang, Eul Chul ^c   Lee, Young Deuk ^d   Liu, Kwang Hyeon ^a,e   Kim, Jeong Han ^a,e  

^a Seoul National University   (South Korea)

^b Wonkwang University   (South Korea)

^c Dong A University   (South Korea)

^d Daegu University   (South Korea)

^e Inje University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; COMPLEMENTARY DNA; CYTOCHROME P450 2B6; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 ISOENZYME; ENDOSULFAN; ENDOSULFAN SULFATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; CORRELATION ANALYSIS; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EFFECT; DRUG HYDROXYLATION; DRUG METABOLISM; ENANTIOSELECTIVITY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER; LIVER MICROSOME; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STEREOCHEMISTRY; SULFONATION;

ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; ENDOSULFAN; ENZYME INHIBITORS; HUMANS; INSECTICIDES; KETOCONAZOLE; KINETICS; MICROSOMES, LIVER; OXIDOREDUCTASES, N-DEMETHYLATING; RECOMBINANT PROTEINS; STEREOISOMERISM; THIOTEPA;

EID: 33745255092     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.105.009134     Document Type: Article

References (38)

1. Abelo A, Andersson TB, Antonsson M, Naudot AK, Skanberg I, and Weidolf L (2000) Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metab Dispos 28:966-972.
2. Awasthi N, Singh AK, Jain RK, Khangarot BS, and Kumar A (2003) Degradation and detoxification of endosulfan isomers by a defined co-culture of two Bacillus strains. Appl Microbiol Biotechnol 62:279-283.
3. Barnes WW and Ware GW (1965) The absorption and metabolism of C-14-labeled endosulfan in the house fly. J Econ Entomol 58:286-291.
4. Buratti FM, D'Aniello A, Volpe MT, Meneguz A, and Testai E (2005) Malathion bioactivation in the human liver: the contribution of different cytochrome P450 isoforms. Drug Metab Dispos 33:295-302.
5. Chambers JE, Chambers HW, and Snawder JE (1991) Target site bioactivation of the neurotoxic organophosphorus insecticide parathion in partially hepatectomized rats. Life Sci 48:1023-1029.
6. El Beit IO, Wheelock JV, and Cotton DE (1981) Factors affecting soil residues of dieldrin, endosulfan, gamma-HCH, dimethoate and pyrolan. Ecotoxicol Environ Saf 5:135-160.
7. Faucette SR, Hawke RL, Lecluyse EL, Shord SS, Yan B, Laethem RM, and Lindley CM (2000) Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos 28:1222-1230.
8. Gervot L, Rochat B, Gautier JC, Bohnenstengel F, Kroemer H, de Berardinis V, Martin H, Beaune P, and de Waziers I (1999) Human CYP2B6: expression, inducibility and catalytic activities. Pharmacogenetics 9:295-306.
9. Hanna IH, Reed JR, Guengerich FP, and Hollenberg PF (2000) Expression of human cytochrome P450 2B6 in Escherichia coli: characterization of catalytic activity and expression levels in human liver. Arch Biochem Biophys 376:206-216.
10. Hariparsad N, Nallani SC, Sane RS, Buckley DJ, Buckley AR, and Desai PB (2004) Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital. J Clin Pharmacol 44:1273-1281.
11. Hesse LM, von Moltke LL, Shader RI, and Greenblatt DJ (2001) Ritonavir, efavirenz and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion. Drug Metab Dispos 29:100-102.
12. Kaur I, Kumar A, and Duraja P (1997) Separation of endosulphan and its major metabolites by GC and HPLC. Biomed Chromatogr 11:33-35.
13. Kennedy IR, Sanchez-Bayo F, Kimber SW, Hugo L, and Ahmad N (2001) Off-site movement of endosulfan from irrigated cotton in New South Wales. J Environ Qual 30:683-696.
14. Kim H, Yoon YJ, Kim H, Cha EY, Lee HS, Kim JH, Yi KY, Lee S, Cheon HG, Yoo SE, et al. (2005a) In vitro metabolism of a new cardioprotective agent, KR-33028 in the human liver microsomes and cryopreserved human hepatocytes. Arch Pharm Res (Seoul) 28:1287-1292.
15. Kim KA, Kim MJ, Park JY, Shon JH, Yoon YR, Lee SS, Liu KH, Chun JH, Hyun MH, and Shin JG (2003) Stereoselective metabolism of lansoprazole by human liver cytochrome P450 enzymes. Drug Metab Dispos 31:1227-1234.
16. Kim MJ, Kim H, Cha IJ, Park JS, Shon JH, Liu KH, and Shin JG (2005b) High-throughput screening of inhibitory potential of nine cytochrome P450 enzymes in vitro using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 19:2651-2658.
17. Kullman SW and Matsumura F (1996) Metabolic pathways utilized by Phanerochaete chrysosporium for degradation of the cyclodiene pesticide endosulfan. Appl Environ Microbiol 62:593-600.
18. Lang T, Klein K, Fischer J, Nussler AK, Neuhaus P, Hofmann U, Eichelbaum M, Schwab M, and Zanger UM (2001) Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 11:399-415.
19. Liu KH and Kim JH (2003) In vitro dermal penetration study of carbofuran, carbosulfan and furathiocarb. Arch Toxicol 77:255-260.
20. Liu KH, Sung HJ, Lee HK, Song BH, Ihm YB, Kim K, Lee HS, and Kim JH (2002) Dermal pharmacokinetics of the insecticide furathiocarb in rats. Pest Manag Sci 58:57-62.
21. Maenpaa J, Pelkonen O, Cresteil T, and Rane A (1993) The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol 44:61-67.
22. Martinez Vidal JL, Arrebola FJ, Fernandez-Gutierrez A, and Rams MA (1998) Determination of endosulfan and its metabolites in human urine using gas chromatography-tandem mass spectrometry. J Chromatogr B Biomed Sci Appl 719:71-78.
23. Neuvonen PJ, Kantola T, and Kivisto KT (1998) Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 63:332-341.
24. Pike MG, Mays DC, Macomber DW, and Lipsky JJ (2001) Metabolism of a disulfiram metabolite, S-methyl N,N-diethyldithiocarbamate, by flavin monooxygenase in human renal microsomes. Drug Metab Dispos 29:127-132.
25. Rodrigues AD (1999) Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem Pharmacol 57:465-480.
26. Shimada T, Yamazaki H, Mimura M, Inui Y, and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423.
27. Shin JG, Soukhova N, and Flockhart DA (1999) Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6. Drug Metab Dispos 27:1078-1084.
28. Stresser DM and Kupfer D (1999) Monospecific antipeptide antibody to cytochrome P-450 2B6. Drug Metab Dispos 27:517-525.
29. Surapaneni SS, Clay MP, Spangle LA, Paschal JW, and Lindstrom TD (1997) In vitro biotransformation and identification of human cytochrome P450 isozyme-dependent metabolism of tazofelone. Drug Metab Dispos 25:1383-1388.
30. Sutherland TD, Horne I, Lacey MJ, Harcourt RL, Russell RJ, and Oakeshott JG (2000) Enrichment of an endosulfan-degrading mixed bacterial culture. Appl Environ Microbiol 66:2822-2828.
31. Tang J, Amin Usmani K, Hodgson E, and Rose RL (2004) In vitro metabolism of fipronil by human and rat cytochrome P450 and its interactions with testosterone and diazepam. Chem-Biol Interact 147:319-329.
32. Tang J, Cao Y, Rose RL, Brimfield AA, Dai D, Goldstein JA, and Hodgson E (2001) Metabolism of chlorpyrifos by human cytochrome P450 isoforms and human, mouse and rat liver microsomes. Drug Metab Dispos 29:1201-1204.
33. Tang J, Cao Y, Rose RL, and Hodgson E (2002) In vitro metabolism of carbaryl by human cytochrome P450 and its inhibition by chlorpyrifos. Chem-Biol Interact 141:229-241.
34. Usmani KA, Hodgson E, and Rose RL (2004a) In vitro metabolism of carbofuran by human, mouse, and rat cytochrome P450 and interactions with chlorpyrifos, testosterone and estradiol. Chem-Biol Interact 150:221-232.
35. Usmani KA, Karoly ED, Hodgson E, and Rose RL (2004b) In vitro sulfoxidation of thioether compounds by human cytochrome P450 and flavin-containing monooxygenase isoforms with particular reference to the CYP2C subfamily. Drug Metab Dispos 32:333-339.
36. Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, and Desta Z (2003) The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 306:287-300.
37. Westlind A, Lofberg L, Tindberg N, Andersson TB, and Ingelman-Sundberg M (1999) Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5′-upstream regulatory region. Biochem Biophys Res Commun 259:201-205.
38. Wrighton SA, Brian WR, Sari MA, Iwasaki M, Guengerich FP, Raucy JL, Molowa DT, and Vandenbranden M (1990) Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol Pharmacol 38:207-213.